Preferred Label : Leuprolide Mesylate Injectable Suspension;
NCIt synonyms : LMIS;
NCIt definition : A depot suspension for injection composed of the mesylate salt of leuprolide, a synthetic,
long-acting nonapeptide analog of the endogenous hormone gonadotropin-releasing hormone
(GnRH), with potential antineoplastic activity. Upon subcutaneous injection of the
depot suspension, leuprolide binds to and activates the gonadotropin-releasing hormone
receptor (GnRHR). The continuous stimulation of GnRHR by leuprolide results in both
the desensitization of pituitary GnRHR and the inhibition of pituitary secretion of
the gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH).
In males, this results in a significant decline in testosterone production to castration
levels and may inhibit androgen receptor-positive tumor progression.;
Origin ID : C118363;
UMLS CUI : C3896651;
False automatic mappings
- Semantic type(s)
- chemical_or_drug_affects_gene_product
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
https://www.ema.europa.eu/en/medicines/human/EPAR/camcevi
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
leuprolide
leuprolide
prostatic neoplasms
neoplasms, hormone-dependent
advanced hormone-dependent prostate cancer
antineoplastic agents, hormonal
antineoplastic agents, hormonal
adult
drug approval
europe
aged
Delayed-Action preparations
injections, subcutaneous
drug interactions
Leuprolide Mesylate Injectable Suspension
Product containing only leuprorelin in parenteral dose form (medicinal product form)
leuprorelin
drug evaluation, preclinical
---
